10-Mar-2026      10:36

Jagsonpal Pharma sizzles as board to mull buyback proposal

As on 31st December 2025, the company's promoter shareholding stood at 67.39%.

Jagsonpal Pharmaceuticals has portfolio of drugs focusing on gynaecology, orthopaedics, dermatology and child-care segments.

The company's standalone net profit fell 8.4% to Rs 12.49 crore on 1.5% fall in net sales to Rs 72.95 crore in Q3 FY26 compared with Q3 FY25.

Powered by Capital Market - Live News

News source: Capital Market - Live News